Reduction in Asthma Deteriorations in Subjects With Persistent Asthma Uncontrolled on Low-, Medium-, or High-Dose Inhaled Corticosteroids: A Pooled Analysis From Three Clinical Trials Using Combined Mometasone Furoate/Formoterol

Reduction in Asthma Deteriorations in Subjects With Persistent Asthma Uncontrolled on Low-, Medium-, or High-Dose Inhaled Corticosteroids: A Pooled Analysis From Three Clinical Trials Using Combined Mometasone Furoate/Formoterol

Assessment of asthma deterioration (ie, 20% decrease in forced expiratory volume in 1s [FEV1]; 30% decrease in peak expiratory flow [PEF] on >=2 consecutive days; or clinically judged deterioration [ie, emergency treatment, hospitalization, or treatment with excluded medications]) was a co-primar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2011-02, Vol.127 (2), p.AB86-AB86
Hauptverfasser: Weinstein, S.F, Nathan, R.A, Meltzer, E.O, Gates, D, Nolte, H
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Asthma
Clinical trials
Drug therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Assessment of asthma deterioration (ie, 20% decrease in forced expiratory volume in 1s [FEV1]; 30% decrease in peak expiratory flow [PEF] on >=2 consecutive days; or clinically judged deterioration [ie, emergency treatment, hospitalization, or treatment with excluded medications]) was a co-primary endpoint for studies P04073/P04334, and a secondary endpoint for study P04431.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2010.12.349